ImpriMed, Inc.

📍 Palo Alto, United States🗓 Founded 2017👥 46 employees💰 Last funded Nov 2023
Biotechnology Research🌐 imprimedicine.com
Website LinkedIn
ImpriMed, founded in 2017 in Silicon Valley, is a leading precision medicine startup revolutionizing cancer treatment with artificial intelligence. The company’s pioneering drug response prediction technology helps reduce costs, accelerate treatment, enhance efficacy, and improve the quality of life for patients. To date, the company’s technology has been deployed across more than 40 U.S. states, and 22,000+ canine and feline blood cancer tests have been performed as of 2025. ImpriMed is now poised to extend its groundbreaking AI-driven approach to human healthcare, redefining the future of oncology treatment with personalized, effective solutions. For additional information, visit www.imprimedicine.com.
4
Total investors
1
Early stage
0
Mid stage
3
Late stage
2017
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
3
Korea
1
Investor activity2019–2023 · investors recorded per year
2019120233
Recent (last 2y)Earlier
Frequently asked questions
Who invested in ImpriMed, Inc.?
ImpriMed, Inc. has 4 investors on record on gritt.io, including 1 early-stage backers and 3 late-stage investors.
When did ImpriMed, Inc. last raise funding?
The most recent investment in ImpriMed, Inc. recorded on gritt.io was in November 2023.
When was ImpriMed, Inc. founded?
ImpriMed, Inc. was founded in 2017.
What industry is ImpriMed, Inc. in?
ImpriMed, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ImpriMed, Inc. based?
ImpriMed, Inc. is headquartered in Palo Alto, United States.